(415) 353-7070 (appts)
(415) 353-9571 (fax)

Box 1710, UCSF; San Francisco, CA 94143-1710,

additional websites:

UCSF Physician Referral Directory

Harvard College, A.B., 1982, Biochemical Sciences
Stanford University School of Medicine, M.D., 1986, Medicine
University of Calilfornia, Los Angeles, Residency, 1989, Internal Medicine
University of California San Francisco, Fellowship, 1992, Medical Oncology & Hematology

selected from > 65 papers

Holmes WE et al. Identification of heregulin, a specific activator of p185erbB2. Science 1992, 256:1205.

Park JW, Stagg R, Lewis GD, Carter P, Maneval D, Slamon DJ, Jaffe H & Shepard HM. Anti-p185HER2 MAbs: biological properties and potential for immunotherapy, Breast Cancer Res. Treat. 1992, 61:193-211.

Scott GK et al. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol. Cell. Biol. 1993, 13:2247-2257.

Park JW et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA 1995, 92:1327-1331.

Li W, Park JW, Nuijens A, Sliwkowski MX & Keller G-A. Heregulin is rapidly translocated to the nucleus and is associated with c-myc induction in breast cancer cells. Oncogene 1996, 12:2473-2477.

Kirpotin D, Park JW et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cell in vitro. Biochemistry 1997, 36:66-75.

Chang CH et al. Epithelium restricted ets with unique structural features overexpressed early during human breast tumorigenesis. Oncogene 1997, 14:1617-1622.

Meyer O, Kirpotin D, Hong K, Sternberg B, Park JW & Papahadjopoulos D. Targeted poly(ethylene glycol)-modified cationic liposomes for antisense oligonucleotide delivery, J. Biol. Chem. 1998, 273: 15621-15627.

Lackey DB et al. Enzyme catalyzed therapeutic agent design: the antitumor ECTA compound NB1011 is activated by thymidylate synthase. Biochem. Pharmacol. 2001, 61:179-189.

Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D & Benz CC. Anti-HER2 immunoliposomes: enhanced anticancer efficacy due to targeted delivery. Clin. Cancer Res., 2002, 8:1172-1181.

Nielsen UB et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta 2002, 1591(1-3):109-118.

Nagy P et al. Lipid rafts and the local concentration of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J. Cell Sci., 2002, 115: 4251-4262.

Mamot C, Drummond D, Greiser U, Hong K, Kirpotin DB, Marks JD & Park JW. EGFR-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003, 63:3154-3161

Mamot C et al. Extensive distribution of liposomes in rodent brains and brain tumors following convection enhanced delivery (CED), J. NeuroOncol. 2004, 68:1-9.

Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Park JW, Berger MS & Bankiewicz KS. Distribution of liposomes into brain and rat brain-tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 2004, 64:2572-2579.

Kelloff GJ, Bast RC, Coffey DS, DÕAmico AV, Kerbel RS, Park JW, Ruddon RW, Rustin JS, Schilsky RL, Sigman CC & Vande Woude GF. Prologue: surrogate endpoints and the need for accelerating cancer drug development. Clin. Cancer Res. 2004, 10:3881-3884.

Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Phillips R, Ruddon RW, Sigman CC & Slamon DJ. Rationale for biomarkers and surrogate endpoints in mechanism-driven oncology drug development. Clin. Cancer Res. 2004, 10:3885-3896.

Rini BI, Weinberg V, Shaw V, Bok R, Park JW, Scott J & Small EJ. Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. Cancer 2004, 101(1):90-5.

Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, Broadt TL, Ouellette TF, Perkins SC, Roach JM, Drummond DC, Hong K, Marks JD, Park JW, and Giardina SL. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol. Progress 2005, 21 (1), 205 -220.

Nellis DF, Giardina SL, Janini G, Shenoy SR, Marks JD, Tsai R, Drummond DC, Hong K, Park JW, Ouellette TF, Perkins SC, and Kirpotin DB. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 2. Conjugate micelle identity, purity, stability and potency analysis. Biotechnol. Progress 2005, 21 (1), 221 -232.

Melisko ME, Kunwar S, Prados M, Berger MS, and Park JW. Brain metastases of breast cancer. Expert Rev. Anticancer Ther. 2005, 5(2):253-68.

Campbell MJ, Scott J, Maecker H, Park JW, and Esserman LJ. Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res. Treat. 2005, 91(2):163-71.

Drummond DC, Marx C, Guo Z, Scott G, Noble C, Wang D, Pallavicini M, Park JW, Kirpotin DB, and Benz CC. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res. 2005, 11(9):3392-401.

Horv‡th G, Mikl—s Petr‡s M, Szentesi G, F‡bi‡n A, Park JW, Vereb G, and Szšllsi J. Selecting optimal fluorophores and flow cytometer for fluorescence resonance energy transfer measurements. Cytometry A 2005, 65(2):148-57.

Mocanu MM, Fazekas Z, Petr‡s M, Nagy P, SebestyŽn Z, Isola J, T’m‡r J, Park JW, Vereb G, and Szšllsi J. Associations of ErbB2, 1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. Cancer Lett. 2005, 227(2): 201-212.

Nagy P, Bene L, Hyun WC, Vereb G, Braun M, Antz C, S‡ndor Damjanovich S, Paysan J, Park JW, and Szšllsi J. Novel calibration method for flow cytometric fluorescence resonance energy transfer measurements between visible fluorescent proteins. Cytometry 2005, 67(2):86-96.

Li K-L, Wilmes, LJ, Henry RG, Maria G. Pallavicini, Park JW, Hu-Lowe DD, McShane TM, Shalinsky, DR, Fu Y-J, Brasch RC, and Hylton NM. Heterogeneity in angiogenic response of BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. J. Magn. Resonance Imaging (JMRI) 2005, 22:511-519.

Saito R, Krauze MT, Bringas JR, Noble C, McKnight TR, Jackson P, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Hong K, Berger MS, Park JW, and Bankiewicz KS. Gadolinium-loaded liposomes allow for real-time M of convection-enhanced delivery in the primate brain. Exp. Neurology 2005, 196:381-9.

Krauze MT, Tracy R. McKnight TR, Yamashita Y, Bringas J, Noble C, Saito R, Geletneky K, Forsayeth J, Park JW, Mitchel S. Berger MS and Bankiewicz KS. Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc. 2005, 16:20-6.

Krauze MT, Saito R, Noble CO, Tamas M, Bringas JR, Park JW, Berger MS, and Bankiewicz KS. Reflux-free cannula for convection-enhanced delivery permitting high-speed delivery of therapeutic agents. J. Neurosurg. 2005, 103(5):923-9.

Krauze MT, Saito R, Noble CO, Bringas JR, McKnight TR, Park JW, and Bankiewicz KS. Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp. Neurology 2005;196(1):104-11.

Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee Jr FT, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD and Herbst RS. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J. Clin. Oncol. 2005, 23(24):5464-73.

Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo J and Wilding G. Phase I trial of the oral anti-angiogenesis agent AG-013736, in patients with advanced solid tumors Ð pharmacokinetic and clinical results. J. Clin. Oncol. 2005, 23(24):5474-83.

Mamot C, Drummond DC, Noble CO, Guo Z, Hong K, Kirpotin DB, and Park JW. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs. Cancer Res. 2005, 2005, 65(24):11631-8.

Noble CO, Krauze MT, Drummond DC, Yamashita Y, Saito R, Kirpotin DB, Bankiewicz KS and Park JW. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res. 2006, 66: 2801-2806.

Drummond D, Noble CO, Guo Z, Hong K, Park JW, and Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006, 66: 3271-3277.

Hayes ME, Drummond DC, Kirpotin DB, Zheng WW, Noble CO IV, Park JW, Marks JD, Benz CC, and Hong K. Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Therapy 2005, Dec 8; [Epub ahead of print].

Saito R, Noble CO, Krauze M, Tamas, M, Drummond DC, Kirpotin DB, Hong K, Park JW, Berger MS, and Bankiewicz KS. Tissue affinity of the infusate affects the volume of distribution during convection enhanced delivery into rodent brains; implications for local drug delivery. J. Neurosci. Methods 2006, Feb 9; [Epub].

Hayes ME, Drummond DC, Hong K, Park JW, Marks JD, Kirpotin DB. Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases. Biochim Biophys Acta 2006, Apr 17; [Epub ahead of print].

Hadaczek P, Mirek H, Tamas L, Bohn M, Noble C, Park JW, and Bankiewicz KS. (2006) Perivascular pump driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Molecular Therapy 2006, Apr 28; [Epub ahead of print].

Saito R, Krauze MT, Noble CO, Drummond DC, Kirpotin DB, Berger MS, Park JW, and Bankiewicz KS. Convection-enhanced delivery of nanoliposomal topotecan enables an effective continuous low-dose chemotherapy against malignant glioma xenograft models. Neuro-Oncology 2006, in press.

Yamashita Y, Saito R, Krauze M, Kawaguchi T, Noble CO, Drummond DC, Kirpotin DB, Pieper RO, Park JW, Berger MS and Bankiewicz KS. Convection-enhanced delivery of liposomal doxorubicin ini intracranial brain tumor xenografts. Targeted Oncology 2006, in press.

Marx C, Berger C, Fan Xu F, Amend C, Johnson J, Scott G, Hann B, Park JW, and Benz CC. Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription. Assay Drug Develop. Technol. 2006, 4: 273-84.

Mamot C, Ritschard R, Küng W, Reuter J, Park JW, Herrmann R and Rochlitz CF. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. J. Drug Targeting 2006, in press.

Kirpotin DB, Drummond DC, Hong K, Shao Y, Shalaby R, Nielsen UB, Marks JD, Benz CC, and Park JW. Antibody targeting of long circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66: 6732-40.

1/2/07